Journal of Infection · 2020 · 70 citations · 23 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial StewardshipBacteriologyMedical MicrobiologyAntibiotic ResistanceBacterial InfectionsBrain AbscessCentral Nervous System InfectionsClinical BacteriologyDiagnostic BacteriologyAdult Brain AbscessAntimicrobial Stewardship MonitoringCerebral Abscess ImagingEtiology Of Brain AbscessMicrobial SurveillanceMicrobiological DiagnosticsPathogenesis Of Brain AbscessStreptococcus Species
BACKGROUND: Brain abscess is an uncommon condition, but carries high mortality. Current treatment guidelines are based on limited data. Surveillance of clinical, radiological and microbiology data is important to inform patient stratification, interventions, and antimicrobial stewardship. METHODS: We undertook a retrospective, observational study of patients with brain abscess, based on hospital coding, in a UK tertiary referral teaching hospital. We reviewed imaging data, laboratory microbiology, and antibiotic prescriptions. RESULTS: Over a 47 month period, we identified 47 adults with bacterial brain abscess (77% male, median age 47 years). Most of the abscesses were solitary frontal or parietal lesions. A microbiological diagnosis was secured in 39/47 (83%) of cases, among which the majority were of the Streptococcus milleri group (27/39; 69%), with a predominance of Streptococcus intermedius (19/27; 70%). Patients received a median of 6 weeks of intravenous antibiotics (most commonly ceftriaxone), with variable oral follow-on regimens. Ten patients (21%) died, up to 146 days after diagnosis. Mortality was significantly associated with increasing age, multiple abscesses, immunosuppression and the presence of an underlying cardiac anomaly. CONCLUSION: Our data suggest that there has been a shift away from staphylococcal brain abscesses, towards S. intermedius as a dominant pathogen. In our setting, empiric current first line therapy with ceftriaxone remains appropriate on microbiological grounds and narrower spectrum therapy may sometimes be justified. Mortality of this condition remains high among patients with comorbidity. Prospective studies are required to inform optimum dose, route and duration of antimicrobial therapy.
23
Oral versus Intravenous Antibiotics for Bone and Joint Infection
Ho Kwong Li, Ines Rombach, Rhea Zambellas et al. · New England Journal of Medicine · 2019 · 900 citations · Full text
Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis
Kasper Iversen, Nikolaj Ihlemann, Sabine Gill et al. · New England Journal of Medicine · 2018 · 790 citations · Full text
Robert A. Whiley, D. Beighton, T.G. Winstanley et al. · Journal of Clinical Microbiology · 1992 · 407 citations · Full text
Philippa C. Matthews, Christopher P. Conlon, Anthony R. Berendt et al. · Journal of Antimicrobial Chemotherapy · 2007 · 166 citations · Full text